Clinical Trial Detail

NCT ID NCT02632448
Title A Study of LY2880070 in Patients With Advanced or Metastatic Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Esperas Pharma Inc.
Indications

colorectal cancer

ovarian cancer

Advanced Solid Tumor

triple-receptor negative breast cancer

Therapies

LY2880070 + Gemcitabine

LY2880070

Age Groups: adult

Additional content available in CKB BOOST